PV Bulletin

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

The Emergency Task Force of the EMA has recommended that marketing authorisation holders update their COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign due to decreased efficacy of existing vaccines.

Primary source: European Medicines Agency (EMA)

PV Impact Brief

MonitoringConfidence: high

What changed

ETF recommended that marketing authorisation holders update their COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign.

Why it matters

Decreased efficacy of existing vaccines against the XFG variant could reduce protection against COVID-19, necessitating vaccine strain updates.

Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

quarterly

Regulatory action details

Action type
Regulatory Recommendation / Public Health Communication
Publication date
2026-05-29
Last updated
2026-05-29
Safety issue
Decreased efficacy of existing vaccines against the evolving XFG variant of COVID-19.

Affected products

  • COVID-19 vaccines
    Marketing authorisation holders (various)

PV internal implications

Requires monitoring of vaccine efficacy signals and potential preparation for strain change variations.

View regulator source

Evidence and confidence

Confidence: highSource updated: May 29, 2026

Full briefing

Practical implication

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

The EMA ETF recommends updating COVID-19 vaccines to target the XFG variant for the 2026/2027 campaign, citing decreased efficacy of current vaccines against the evolving variant.

What changed: ETF recommended that marketing authorisation holders update their COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign.

Why it matters: Decreased efficacy of existing vaccines against the XFG variant could reduce protection against COVID-19, necessitating vaccine strain updates.

Practical implication: Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals#firecrawl-agent#regulatory-extraction#Other#Vaccine Updates#Regulatory Recommendation / Public Health Communication#European Medicines Agency (EMA)

Related updates for your role

publicFDA · USA · Updated Aug 28, 2026

FDA Approves Mimrylo for Polycythemia Vera Treatment

Urgency: High

Patients will be treated with an initial dose of 19 mg of Mimrylo, administered weekly, with careful monitoring to maintain hematocrit levels below 45%. The operation of post-marketing surveillance will be affected due to the introduction of this new drug.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicMHRA · UK · Updated Aug 28, 2026

Record Ketamine Seizures Indicate Safety Concerns

Urgency: High

Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEMA · European Union · Updated Aug 28, 2026

PSUSA/00001088/202512 - Safety Update Amendments for Dimenhydrinate

Urgency: High

Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Aug 28, 2026

Choline Salicylate PSUSA/00000732/202512 - Safety Update Assessment

Urgency: High

Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward